Targeting Histone Acetyltransferase MOZ/KAT6A as a New Avenue for Hematological Tumor Therapy

Author(s): Chongchen Zhou, Hai-liang Zhu*, Yongtao Duan*

Journal Name: Current Topics in Medicinal Chemistry

Volume 20 , Issue 5 , 2020

Become EABM
Become Reviewer

Duan, Y-T.; Sangani, C.B.; Liu, W.; Soni, K.V.; Yao, Y. New promises to cure cancer and other genetic diseases/disorders: Epi-drugs through epigenetics. Curr. Top. Med. Chem., 2019, 19(12), 972-994.
Liu, W.; Wang, X.; Zhu, H.; Duan, Y. Precision tumor medicine and drug targets. Curr. Top. Med. Chem., 2019, 19(17), 1488-1489.
Huang, F.; Abmayr, S.M.; Workman, J.L. Regulation of KAT6 acetyltransferases and their roles in cell cycle progression, stem cell maintenance, and human disease. Mol. Cell. Biol., 2016, 36(14), 1900-1907.
Leaver, D.J.; Cleary, B.; Nguyen, N.; Priebbenow, D.L.; Lagiakos, H.R.; Sanchez, J.; Xue, L.; Huang, F.; Sun, Y.; Mujumdar, P. Discovery of benzoylsulfonohydrazides as potent inhibitors of the histone acetyltransferase KAT6A. J. Med. Chem., 2019, 62(15), 7146-7159.
Baell, J.B.; Leaver, D.J.; Hermans, S.J.; Kelly, G.L.; Brennan, M.S.; Downer, N.L.; Nguyen, N.; Wichmann, J.; McRae, H.M.; Yang, Y. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. Nature, 2018, 560(7717), 253-257.
Kaur, M.; Rawal, R.K.; Rath, G.; Goyal, A.K. Structure based drug design: clinically relevant hiv-1 integrase inhibitors. Curr. Top. Med. Chem., 2018, 18(31), 2664-2680.
Horton, J.R.; Woodcock, C.B.; Chen, Q.; Liu, X.; Zhang, X.; Shanks, J.; Rai, G.; Mott, B.T.; Jansen, D.J.; Kales, S.C. Structure-based engineering of irreversible inhibitors against histone lysine demethylase KDM5A. J. Med. Chem., 2018, 61(23), 10588-10601.
Duan, Y.; Liu, W.; Tian, L.; Mao, Y.; Song, C. Targeting tubulin-colchicine site for cancer therapy: inhibitors, antibody-drug conjugates and degradation agents. Curr. Top. Med. Chem., 2019, 19(15), 1289-1304.
Xia, L-W.; Ba, M-Y.; Liu, W.; Cheng, W.; Hu, C-P.; Zhao, Q.; Yao, Y-F.; Sun, M-R.; Duan, Y-T. Triazol: a privileged scaffold for proteolysis targeting chimeras. Future Med. Chem., 2019, 11(22), 2919-2973.
Xia, L.; Liu, W.; Song, Y.; Zhu, H.; Duan, Y. The present and future of novel protein degradation technology. Curr. Top. Med. Chem., 2019, 19(20), 1784-1788.

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [333 - 335]
Pages: 3
DOI: 10.2174/156802662005200304123442

Article Metrics

PDF: 35
HTML: 10